Clinical trials: Patients with Multiple Sclerosis
Multiple Sclerosis
Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe
Determine patient satisfaction with the single-use autoinjector for the delivery of pre-filled Avonex syringe.
- Trial name
- NCT00915577
- Testing
- Interferon beta-1a, Single-use autoinjector
- Volunteers
- 74 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis
Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.
- Trial name
- Biobank (NCT01310166)
- Testing
- Fingolimod
- Where
- 61 sites in Germany
- Volunteers
- 447 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body.
- Trial name
- EXO-MOBILITY (NCT07252895)
- Testing
- EXOPULSE Suit in Active mode
- Where
- 11 sites in France
- Volunteers
- 77 people
- Sponsor
- Otto Bock France SNC
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)
Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol.
- Trial name
- NCT01039103
- Testing
- PEG-liposomal prednisolone sodium phosphate, Methylprednisolone
- Where
- 8 sites in Belgium, Germany and 1 more
- Volunteers
- 15 people
- Sponsor
- Lakefront Biotherapeutics NV
Relapsing Remitting Multiple Sclerosis
Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy
The primary objective of the study is to evaluate safety and tolerability as defined by the frequency of the adverse events (AEs) of flu-like symptoms (FLS) [chills, pyrexia, myalgia, and asthenia], injection site reactions…
- Trial name
- PLENO (NCT03177083)
- Testing
- peginterferon beta-1a, interferon beta-1a, interferon beta-1b
- Where
- 15 sites in Portugal
- Volunteers
- 80 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
This study is to identify the safety and efficacy of repeat IV(Intravenous) and IT(Intrathecal) administrations of UMSC01 in patients with MS.
- Trial name
- UMSC01 (NCT05532943)
- Testing
- Allogeneic umbilical cord mesenchymal stem cells, Control group
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Ever Supreme Bio Technology Co., Ltd.
Multiple Sclerosis
Immunogenicity and Safety Study of Serum-Free Avonex
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.
- Trial name
- NCT00912860
- Testing
- Interferon beta-1a
- Volunteers
- 155 people
- Sponsor
- Biogen
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms
To evaluate the safety and tolerability of oral administration of PTL201 for relief of spasticity-related symptoms in 70 MS patients and to evaluate the efficacy of oral administration of PTL201 in relief of spasticity-related…
- Trial name
- NCT03005119
- Testing
- PTL201
- Where
- Israel
- Volunteers
- 70 people
- Sponsor
- PhytoTech Therapeutics, Ltd.
Multiple Sclerosis
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
This study will primarily compare the long-term effects of an early and continued treatment with Betaferon/Betaseron (patients who were treated with active medication during the double-blind BENEFIT study) to treatment initiated…
- Trial name
- NCT00185211
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 94 sites in Austria, Belgium and 18 more
- Volunteers
- 468 people
- Sponsor
- Bayer
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Multiple Sclerosis, Relapsing-Remitting
Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis
This study aims to calibrate the Multiple Sclerosis Functional Composite (MSFC) for home implementation in a phase 2 trial of lisinopril in multiple sclerosis.
- Trial name
- NCT02369926
- Testing
- Multiple Sclerosis Functional Composite, Mobile Multiple Sclerosis Functional Composite
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Transparency Life Sciences
Tuberous Sclerosis, Angiofibroma
Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)
The purpose of this trial is to evaluate the efficacy and safety of NPC-12G gel (topical formulation of sirolimus) versus placebo gel to facial angiofibroma and other skin lesions in patients with tuberous sclerosis complex (TSC)
- Conditions
- Tuberous Sclerosis, Angiofibroma, Hypomelanotic Macule, Plaque
- Trial name
- NCT02635789
- Testing
- NPC-12G gel
- Where
- Japan
- Volunteers
- 62 people
- Sponsor
- Nobelpharma
Multiple Sclerosis, Relapsing-Remitting
Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis
The purpose of this study is to determine if natalizumab in combination with Glatiramer Acetate (GA) is safe and effective in delaying progression of individuals diagnosed with relapsing-remitting Multiple Sclerosis (MS).
- Trial name
- NCT00097760
- Testing
- Natalizumab
- Volunteers
- 110 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing Multiple Sclerosis
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
To assess safety and tolerability of patients converting from approved Relapsing Multiple Sclerosis (RMS) Disease Modifying Therapies (DMTs) to siponimod.
- Conditions
- Multiple Sclerosis, Relapsing Multiple Sclerosis, Advancing Multiple Sclerosis
- Trial name
- EXCHANGE (NCT03623243)
- Testing
- Siponimod
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
- Trial name
- NCT01080014
- Where
- Argentina
- Volunteers
- 252 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Progressive Multiple Sclerosis
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after a single subcutaneous (SC) dose in men and women with progressive multiple sclerosis.
- Trial name
- NCT02977533
- Testing
- GZ402668, Acyclovir
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Sanofi
Relapsing Forms of Multiple Sclerosis
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
The primary objective of the study is to estimate the annualized relapse rate (ARR) over a 12-month period in patients with relapsing forms of multiple sclerosis (MS) who are treated with dimethyl fumarate (DMF) after suboptimal…
- Trial name
- RESPOND (NCT01903291)
- Testing
- dimethyl fumarate
- Where
- 62 sites in United States
- Volunteers
- 333 people
- Sponsor
- Biogen
Multiple Sclerosis
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.
- Trial name
- NCT01874340
- Testing
- AIN457
- Where
- 13 sites in Belgium, Czechia and 8 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis
The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day [mg/day] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical…
- Trial name
- TOPIC (NCT00622700)
- Testing
- Teriflunomide
- Where
- 131 sites in United States, Australia and 19 more
- Volunteers
- 618 people
- Sponsor
- Sanofi